However, it contradicts qualitative findings suggesting that cancer patients do distinguish IDH mutation between

dimensions of trust [11] and [26]. This apparent discrepancy deserves further research attention. As yet, it appears difficult to quantitatively expose patients’ possible distinction between trust dimensions. Further validation among specific groups of cancer patients with likely more varying levels of trust should be conducted, e.g., among second opinion patients, immigrants, or patients in palliative care, to investigate if the TiOS is responsive to more pronounced dimensionality and varying trust levels. The current results contribute to research on cancer patients’ trust in their oncologist. Use of the TiOS allows further expansion of this field of study, resulting in better insight into the nature, predictors, and consequences of cancer patients’ trust. Confidence in the

cross-cultural validity of the TiOS enables its use in different countries, allowing direct comparisons between patients’ trust levels internationally. Ultimately, this could improve patient care. Our findings suggest that the English translation of the Trust in Oncologist Scale is suitable for use among English-speaking cancer patients in Australia and other countries with similarly organized health care systems. For the present we suggest that when applying the TiOS, a single score can be used. However, for a more refined understanding of patients’ trust, one might test whether patients in a specific sample distinguish check details different dimensions of trust. This study was financially supported by the Dutch Cancer Society (Grant number: UVA 2008-4015). In addition, Marij Hillen received a travel grant from the Dutch Cancer Society. We would like to acknowledge Karen Bird for her kind assistance in the PtdIns(3,4)P2 recruitment of patients. “
“Cardiovascular disease (CVD) is the leading cause of death in the industrialized world [1] and [2]. Dyslipidemia is an important

risk factor for CVD, estimated to cause 18% of cerebrovascular disease and 56% of ischemic heart disease [3]. Cholesterol lowering has been the primary goal of therapies aimed at CVD risk reduction, and several randomized studies have demonstrated the benefits of statins (hydroxymethylglutaryl-CoA reductase inhibitors) in the reduction of cardiovascular-related events within high-risk patient groups [4]. Currently, statin drug treatment is one of the most important treatment strategies when managing patients with, or at high risk of, CVD. Adherence is defined as the extent to which a person’s behavior, such as taking medication, following a diet or executing lifestyle changes, corresponds with the recommendations from a health care provider [5].